Paris, France,  – CID SpA, a leading company in interventional medicine, have released their 6-month clinical data for the NEXT trial during the Late Breaking Trials session at Euro PCR 2011. This prospective, international, multicenter and randomized First In Man study compares the new CID reservoir-based polymer-free Cre8™ Drug Eluting Stent (DES) to Taxus^TM Liberté^®.

Didier Carrié, MD, PhD., Chief of the Interventional Cath-Lab at Hôpital de Rangueil, Toulouse (France) and principal investigator of the study, provided the 6-month results. While the study was designed to show that the Cre8™ DES was equivalent to TAXUS^TM Liberté^® in patients with coronary artery disease, the Cre8™ proved to be superior at 6 months in terms of late lumen loss with high statistically significant difference (p<0.0001) between stents (0.14±0.36 mm CRE8™ vs. 0.34±0.40 mm Taxus). 

Commenting on the innovative technology of the new Cre8^TM DES and the clinical results obtained in the NEXT study, Franco Vallana, President and C.E.O. of CID SpA stated, “As we move closer to launching our newest DES, we become more and more aware of how important these findings will be for cardiologists and their patients. This is the lowest value ever achieved for Late Lumen Loss with a polymer free platform. With Cre8, cardiologists will now have a DES that has none of the drawbacks associated with polymers. In addition, because our stent has a Bio Inducer Surface, we hope that physicians will be able to shorten the dual antiplatelet therapy period for their patients and reduce the high cost of care as well as the side effects of those drugs.”

Source: CID SpA